Liquidia Corporation's lead drug Yutrepia generated approximately $130 million in sales in the first quarter of 2026, helping the company achieve its third consecutive profitable quarter with net income of $52.9 million. Launched in June 2025 after FDA approval in May 2025 for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, Yutrepia is an inhaled dry-powder formulation of treprostinil using Liquidia's PRINT technology. As of April 30, 2026, the drug had received more than 4,500 unique patient prescriptions since launch, with approximately 3,750 patients initiating treatment and a prescription-to-start conversion rate of 85% or higher. More than 980 physicians have prescribed Yutrepia, and the number of physicians who have prescribed it to at least five patients rose about 25% from the end of February to approximately 270. Liquidia faces competition in the PAH market from United Therapeutics' treprostinil-based products and Johnson & Johnson's Uptravi and Opsumit, among other therapies.
Liquidia Technologies IncYutrepia generated $130M in Q1 sales, driving third consecutive profitable quarter.
United Therapeutics CorporationLiquidia's Yutrepia competes with United Therapeutics' treprostinil-based products.
Johnson & JohnsonLiquidia's Yutrepia competes with J&J's Uptravi and Opsumit in the PAH market.